Tramadol Vitabalans: Uses, Dosage & Side Effects
A prescription opioid analgesic containing tramadol hydrochloride 50 mg, used for moderate to severe pain in adults and adolescents over 12 years
Tramadol Vitabalans is a prescription opioid analgesic containing the active substance tramadol hydrochloride 50 mg, manufactured by Vitabalans Oy. It is used to treat moderate to severe pain in adults and adolescents over 12 years of age. Tramadol has a unique dual mechanism of action: weak agonism at mu-opioid receptors combined with inhibition of serotonin and norepinephrine reuptake. While classified as a weaker opioid compared to morphine or oxycodone, Tramadol Vitabalans carries significant risks including dependency, tolerance, serotonin syndrome, seizures, and respiratory depression, and should only be used under medical supervision for the shortest duration necessary.
Quick Facts: Tramadol Vitabalans
Key Takeaways
- Tramadol Vitabalans is a 50 mg immediate-release tablet containing tramadol hydrochloride, a centrally acting opioid analgesic used for moderate to severe pain. It works through two complementary mechanisms: weak mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake.
- Dependency, tolerance, and abuse can develop with repeated use. Risk increases with higher doses and longer treatment duration. Tramadol is classified as a controlled substance in many countries and must be stored securely.
- Never stop Tramadol Vitabalans abruptly after prolonged use. Withdrawal symptoms including anxiety, tremor, sweating, insomnia, and gastrointestinal distress can occur. Always taper gradually under medical supervision.
- Tramadol Vitabalans must not be combined with MAO inhibitors and carries a serious risk of serotonin syndrome when used with antidepressants (SSRIs, SNRIs, tricyclics). Combining with benzodiazepines or alcohol substantially increases the risk of respiratory depression and death.
- The maximum recommended daily dose is 400 mg (eight 50 mg tablets). Exceeding this significantly increases the risk of seizures. Children under 12 should not use Tramadol Vitabalans, and dose adjustments are required in elderly patients and those with kidney or liver impairment.
What Is Tramadol Vitabalans and What Is It Used For?
Tramadol Vitabalans is a prescription medication belonging to the opioid analgesic class, manufactured by the Finnish pharmaceutical company Vitabalans Oy. Each tablet contains 50 mg of the active substance tramadol hydrochloride. Tramadol itself was originally developed in Germany in the late 1970s by Grünenthal GmbH and has been available on the global market since the 1990s. Today it is one of the most widely prescribed opioid analgesics worldwide, available as a generic medicine from numerous manufacturers under a variety of brand names.
Unlike classical opioids such as morphine or oxycodone, tramadol has a unique dual mechanism of action. Its primary pharmacological effects come from two distinct pathways. First, tramadol and its active metabolite O-desmethyltramadol (M1) bind to mu-opioid receptors in the central nervous system, producing analgesic effects similar to other opioids but with lower affinity. The M1 metabolite has approximately 200 times greater affinity for the mu-opioid receptor than the parent compound and is responsible for a significant portion of the analgesic effect. Second, tramadol inhibits the reuptake of serotonin (5-HT) and norepinephrine in the brain and spinal cord, enhancing descending inhibitory pain pathways. This dual action means tramadol provides pain relief through both opioid and monoaminergic mechanisms, which partly explains why its clinical profile differs from traditional opioids.
Tramadol is metabolized in the liver by the cytochrome P450 enzyme CYP2D6. Genetic variation in this enzyme can significantly affect how individuals respond to Tramadol Vitabalans. Approximately 5–10% of people of European ancestry are poor metabolizers, producing less of the active M1 metabolite and potentially experiencing inadequate pain relief. Conversely, ultra-rapid metabolizers (1–2% of the population) convert tramadol to M1 more quickly and may be at higher risk for serious adverse effects, including respiratory depression. This pharmacogenetic variability is an important clinical consideration that healthcare providers must take into account when selecting pain medications and determining appropriate doses.
Tramadol Vitabalans is officially approved for the treatment of moderate to severe pain in adults and adolescents over 12 years of age. Common clinical indications include acute post-operative pain (following surgical procedures), acute pain following trauma or injury, chronic pain conditions such as osteoarthritis and chronic back pain, and cancer-related pain. It is positioned on step 2 of the World Health Organization (WHO) pain ladder, which recommends weak opioids for moderate pain not adequately controlled by non-opioid analgesics alone. While tramadol may be considered for neuropathic pain, its use in this indication is generally second-line to dedicated neuropathic pain agents such as gabapentin or pregabalin.
As a 50 mg immediate-release tablet, Tramadol Vitabalans is suited for acute pain management and as-needed dosing, with a relatively rapid onset of analgesia (typically within 30–60 minutes) and a duration of action of approximately 4–6 hours per dose. This formulation allows flexible titration to pain control. For patients requiring around-the-clock analgesia for chronic pain conditions, extended-release tramadol formulations from other manufacturers may be more appropriate, as they maintain more stable plasma drug concentrations over a 12-hour period. Your prescribing physician will determine the most suitable formulation based on your specific pain condition and clinical needs.
What Should You Know Before Taking Tramadol Vitabalans?
Contraindications
Tramadol Vitabalans must not be used in certain clinical situations where the risks clearly outweigh any potential benefits. Understanding these absolute contraindications is essential for safe use of this medication. Tramadol Vitabalans is contraindicated if you have a known allergy (hypersensitivity) to tramadol hydrochloride or any of the inactive ingredients in the formulation, as allergic reactions can range from skin rashes and itching to severe anaphylaxis with breathing difficulties, facial swelling, and circulatory collapse.
Tramadol Vitabalans must not be taken during acute intoxication with alcohol, sleeping pills, opiates, or other psychotropic drugs that affect mood or consciousness, as the combination dramatically increases the risk of respiratory depression and central nervous system depression that can be fatal. If you have used monoamine oxidase inhibitors (MAOIs) such as moclobemide, phenelzine, or selegiline within the past 14 days, Tramadol Vitabalans is strictly contraindicated due to the risk of life-threatening serotonin syndrome or hypertensive crisis. Additionally, Tramadol Vitabalans should not be used if you have epilepsy that is not adequately controlled by medication, as it lowers the seizure threshold and can trigger convulsions. Finally, it must not be used as a substitute treatment for opioid withdrawal, as it is not suitable for managing addiction-related withdrawal symptoms.
Warnings and Precautions
Tramadol Vitabalans is an opioid and carries a recognized risk of dependency, tolerance, and misuse. Repeated use can lead to physical and psychological dependence, and life-threatening overdose is possible. The risk is higher with higher doses, longer treatment duration, and in individuals with a history of substance abuse or psychiatric disorders. Never take more than prescribed, use Tramadol Vitabalans for longer than recommended, or take it for purposes other than prescribed.
Before starting Tramadol Vitabalans therapy, it is critical to inform your healthcare provider about your complete medical history. Several conditions require special attention, dose adjustments, or additional monitoring:
- History of substance abuse or dependency: Individuals who have previously been dependent on opioids, alcohol, prescription medications, or illicit drugs are at significantly elevated risk of developing tramadol dependency. This also includes individuals with a family history of addiction.
- Psychiatric conditions: Depression, anxiety disorders, and personality disorders increase the risk of misuse and dependency. If you are being treated by a psychiatrist or taking medications for mental health conditions, your doctor must be informed before starting Tramadol Vitabalans.
- Epilepsy or seizure history: Tramadol lowers the seizure threshold and may trigger convulsions, particularly at doses exceeding 400 mg daily. This risk is further increased when tramadol is combined with SSRIs, SNRIs, tricyclic antidepressants, or antipsychotic medications.
- Head injury or increased intracranial pressure: Tramadol Vitabalans can mask symptoms of head injury and may worsen conditions associated with elevated intracranial pressure. Extreme caution is required in these patients.
- Impaired consciousness: If you experience episodes of lightheadedness, fainting, or altered awareness, Tramadol Vitabalans may exacerbate these symptoms and increase the risk of falls and injury.
- Shock or circulatory failure: Tramadol should not be used in patients experiencing shock, as it can worsen hemodynamic instability.
- Breathing difficulties: Respiratory depression is a serious risk, especially when Tramadol Vitabalans is combined with other CNS depressants. Patients with COPD, sleep apnea, or other respiratory conditions must be closely monitored.
- Kidney or liver disease: Both organs play important roles in tramadol metabolism and elimination. Patients with hepatic or renal impairment require dose adjustments and extended dosing intervals to prevent drug accumulation and toxicity.
Tramadol Vitabalans can cause sleep-related breathing disorders including obstructive sleep apnea and sleep-related hypoxemia (low blood oxygen levels during sleep). Symptoms may include breathing pauses during sleep, nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime drowsiness. If you or someone else notices these symptoms, contact your doctor who may consider dose reduction or an alternative pain treatment.
CYP2D6 metabolizer status: Tramadol is converted in the liver by the CYP2D6 enzyme to its active metabolite O-desmethyltramadol. Genetic variations in CYP2D6 affect individuals differently: poor metabolizers may not receive adequate pain relief, while ultra-rapid metabolizers are at increased risk of serious adverse effects including slow or shallow breathing, confusion, extreme drowsiness, nausea, and vomiting. If you experience any of these symptoms after taking Tramadol Vitabalans, stop the medication and seek immediate medical attention.
Adrenal insufficiency: Long-term opioid use, including tramadol, can rarely cause adrenal insufficiency (low cortisol levels). Symptoms include extreme tiredness, loss of appetite, severe abdominal pain, nausea, vomiting, and low blood pressure. If you develop these symptoms during Tramadol Vitabalans treatment, contact your healthcare provider, who will determine if hormone replacement therapy is necessary.
Opioid-induced hyperalgesia: In some patients, tramadol can paradoxically worsen pain or cause new pain. If you notice that your pain increases after taking Tramadol Vitabalans, experience increased sensitivity to pain, or develop new pain, do not take additional doses. Contact your doctor to discuss alternative treatment options.
Pregnancy and Breastfeeding
Safety data for tramadol use during pregnancy is limited, and Tramadol Vitabalans should generally not be used during pregnancy. Long-term use during pregnancy can lead to neonatal withdrawal syndrome, in which the newborn develops symptoms such as irritability, excessive crying, tremors, jitteriness, vomiting, diarrhea, and feeding difficulties after birth. These symptoms may require specialized neonatal care and can be distressing for both the infant and family.
Tramadol is excreted in breast milk. A single dose does not typically require interruption of breastfeeding. However, if repeated doses are necessary, breastfeeding should be discontinued to avoid infant exposure to the drug and its active metabolite. Based on available human data, tramadol is not believed to significantly affect male or female fertility. Always consult your healthcare provider before using Tramadol Vitabalans if you are pregnant, planning to become pregnant, or breastfeeding so alternative pain management strategies can be considered.
Children and Adolescents
Tramadol Vitabalans is not recommended for children under 12 years of age. It should not be used in children and adolescents with breathing difficulties, as symptoms of tramadol toxicity can be more severe in this population. In adolescents aged 12 and older, Tramadol Vitabalans may be used under close medical supervision with careful attention to dosing and monitoring for adverse effects. The FDA has issued specific warnings against using tramadol in children under 12 and in adolescents aged 12–18 who are obese or have conditions such as obstructive sleep apnea or severe lung disease, due to increased risk of life-threatening respiratory depression.
Driving and Operating Machinery
Tramadol Vitabalans can cause drowsiness, dizziness, and blurred vision, which may impair your ability to react quickly. You should not drive, operate heavy machinery, or engage in activities requiring mental alertness until you know how Tramadol Vitabalans affects you. These effects are more pronounced at the start of treatment, when the dose is increased, or when the medication is combined with alcohol or other CNS depressants. In many countries, driving under the influence of an opioid may carry legal consequences even when the medication has been properly prescribed.
How Does Tramadol Vitabalans Interact with Other Drugs?
Tramadol Vitabalans interacts with numerous medications through various pharmacological mechanisms. Some interactions are life-threatening and constitute absolute contraindications, while others require dose adjustments, additional monitoring, or careful risk-benefit assessment. Understanding these interactions is essential for safe use. The tables below summarize the most clinically significant drug interactions reported with tramadol, the active substance in Tramadol Vitabalans.
Major Interactions
| Drug / Drug Class | Risk | Clinical Advice |
|---|---|---|
| MAO inhibitors (moclobemide, phenelzine, selegiline) | Serotonin syndrome, hypertensive crisis | Absolutely contraindicated. Wait at least 14 days after stopping an MAOI before starting Tramadol Vitabalans. |
| SSRIs (fluoxetine, sertraline, citalopram, escitalopram) | Serotonin syndrome, increased seizure risk | Use only if no alternatives exist. Monitor closely for agitation, hallucinations, rapid heartbeat, fever, muscle rigidity. |
| SNRIs (venlafaxine, duloxetine) | Serotonin syndrome, increased seizure risk | High-risk combination. Careful monitoring required, especially during initiation and dose changes. |
| Tricyclic antidepressants (amitriptyline, nortriptyline, clomipramine) | Serotonin syndrome, increased seizure risk | Avoid if possible. If used together, use the lowest effective doses with close monitoring. |
| Benzodiazepines (diazepam, lorazepam, oxazepam, alprazolam) | Respiratory depression, excessive sedation, coma, death | Use only when no alternative treatment options exist. Limit doses and duration. Monitor breathing closely. |
| Alcohol | Enhanced CNS depression, respiratory depression | Do not consume alcohol during Tramadol Vitabalans treatment. Effects of both substances are dangerously amplified. |
| Other opioids (morphine, codeine, buprenorphine, nalbuphine) | Reduced analgesic effect, respiratory depression | Buprenorphine, nalbuphine, and pentazocine may reduce tramadol's effectiveness. Avoid combination. |
Moderate Interactions
| Drug / Drug Class | Effect | Clinical Advice |
|---|---|---|
| Carbamazepine | Significantly reduces tramadol effectiveness by increasing metabolism | Combination not recommended. Tramadol pain relief may be substantially shortened or eliminated. |
| Ondansetron | May reduce tramadol analgesic effect | Monitor pain control. Alternative anti-emetics may be preferred. |
| Warfarin (coumarins) | Altered anticoagulant effect; increased bleeding risk | Monitor INR closely when starting, adjusting, or stopping Tramadol Vitabalans. Report any unusual bleeding. |
| Gabapentin / Pregabalin | Increased sedation, respiratory depression risk | Use caution. Monitor for excessive drowsiness and breathing difficulties. |
| Antipsychotics (olanzapine, risperidone, quetiapine) | Increased seizure risk, additive CNS depression | Monitor for seizure activity and sedation. Consider alternative pain management where possible. |
| CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) | Reduced conversion to active metabolite M1, lowered analgesic effect | Analgesic response may be inadequate. Alternative pain medication may be required. |
This is not an exhaustive list of all possible interactions. Always inform your healthcare provider and pharmacist about all medications you are taking, including over-the-counter drugs, herbal supplements (such as St John's wort, which also has serotonergic activity), and vitamins. Particular caution is advised with sedating medications, as the combined sedative effect with Tramadol Vitabalans can be dangerous. Inform friends or family members about the signs of excessive sedation and respiratory depression so they can respond appropriately in an emergency by seeking medical help or administering opioid-reversal agents if available.
What Is the Correct Dosage of Tramadol Vitabalans?
Tramadol Vitabalans dosing should be individualized based on the severity of pain, patient response, previous analgesic experience, and risk factors for adverse effects. The fundamental principle of opioid prescribing applies: use the lowest effective dose for the shortest duration necessary. Before starting treatment and at regular intervals during therapy, your doctor should discuss your treatment expectations, duration of use, when to seek medical advice, and when to discontinue treatment. The dosing tables below apply to the Tramadol Vitabalans 50 mg immediate-release tablet.
| Patient Group | Recommended Dose | Maximum Daily Dose |
|---|---|---|
| Adults & adolescents >12 years | 50–100 mg every 4–6 hours as needed | 400 mg (8 tablets) |
| Elderly (>75 years) | 50 mg every 6–8 hours; extend interval as needed | 400 mg (with caution) |
| Mild–moderate renal impairment | 50–100 mg every 12 hours | 200 mg |
| Mild–moderate hepatic impairment | 50–100 mg every 12 hours | 200 mg |
| Severe renal or hepatic impairment | Not recommended | Not recommended |
| Children <12 years | Not recommended | Not recommended |
Adults
Tramadol Vitabalans 50 mg Tablets
Starting dose: 50–100 mg (1–2 tablets) every 4–6 hours as needed for pain.
Titration: Begin with 50 mg. If pain relief is inadequate after one hour, a second 50 mg tablet may be taken. Do not exceed 100 mg as a single dose.
Maximum dose: 400 mg per day (8 tablets of 50 mg).
Administration: Swallow each tablet whole with a glass of water. May be taken with or without food, but taking with food may reduce nausea.
Children and Adolescents
Children Under 12 Years
Tramadol Vitabalans is not recommended for children under 12 years of age due to an unfavorable risk-benefit ratio and serious safety concerns regarding respiratory depression.
Adolescents 12–18 Years
Dosing as for adults (50–100 mg every 4–6 hours as needed, maximum 400 mg per day). Tramadol Vitabalans should not be used in adolescents with breathing difficulties, obesity, obstructive sleep apnea, or other conditions that increase respiratory risk.
Elderly Patients
Patients Over 75 Years
Elimination of tramadol may be slower in elderly patients. Your doctor may recommend extending the interval between doses to every 6–8 hours instead of every 4–6 hours. No specific dose reduction is required if kidney function is normal, but careful monitoring for sedation, confusion, and other adverse effects is important, particularly at the start of treatment.
Kidney and Liver Impairment
Severe Hepatic or Renal Impairment
Patients with severe liver and/or kidney disease should not take Tramadol Vitabalans. For mild to moderate impairment, the dosing interval should be extended (e.g., from every 6 hours to every 12 hours), and the maximum daily dose typically reduced to 200 mg. Your doctor will determine the appropriate regimen based on your specific clinical situation and laboratory values. Dialysis patients may require dosing adjustments, as tramadol is only partially removed by hemodialysis.
Missed Dose
If you forget to take a dose of Tramadol Vitabalans, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten one, as this increases the risk of adverse effects and overdose. If you are using Tramadol Vitabalans for chronic pain management and miss a dose, your pain may return before the next scheduled dose; in such cases, contact your healthcare provider for advice rather than increasing the dose on your own.
Overdose
If you or someone else has taken too many Tramadol Vitabalans tablets, contact emergency services or go to the nearest emergency department immediately. Overdose symptoms include very small (pinpoint) pupils, difficulty breathing or very slow/shallow breathing, unconsciousness or extreme drowsiness, seizures (convulsions), dangerously low blood pressure, nausea and vomiting, and coma. Tramadol overdose can be fatal, especially when combined with alcohol, benzodiazepines, or other CNS depressants. Emergency treatment may include the opioid antagonist naloxone, although naloxone may not fully reverse all tramadol effects (particularly serotonergic effects or seizures), and supportive care is often required.
Stopping Treatment
If you have taken Tramadol Vitabalans for more than a few days, do not stop the medication abruptly. Sudden discontinuation can trigger withdrawal symptoms including anxiety, restlessness, tremor, sweating, insomnia, and gastrointestinal distress. Your doctor will create a personalized tapering schedule that gradually reduces your dose over days to weeks, depending on how long you have been taking the medication and at what dose. Follow the tapering plan carefully and do not make changes without consulting your healthcare provider.
What Are the Side Effects of Tramadol Vitabalans?
Like all medications, Tramadol Vitabalans can cause side effects, although not everyone experiences them. Most side effects are dose-dependent and tend to improve as your body adjusts to the medication, typically within the first week of treatment. However, some side effects are serious and require immediate medical attention. The following side effect frequency grid organizes adverse effects by how commonly they occur, based on clinical trial data and post-marketing surveillance of tramadol-containing products.
Stop taking Tramadol Vitabalans and contact emergency services immediately if you experience: difficulty breathing or wheezing, swelling of the face, tongue, or throat, severe skin rash or hives, seizures (convulsions), or signs of anaphylactic shock (sudden circulatory collapse with pale skin, weak pulse, and loss of consciousness).
Very Common
Affects more than 1 in 10 people
- Dizziness
- Nausea
Common
Affects up to 1 in 10 people
- Headache
- Drowsiness (somnolence)
- Vomiting
- Constipation
- Dry mouth
- Fatigue
- Sweating (hyperhidrosis)
Uncommon
Affects up to 1 in 100 people
- Heart palpitations, rapid heart rate (tachycardia)
- Feeling faint or collapsing (postural hypotension)
- Retching, stomach discomfort, bloating, diarrhea
- Skin reactions: itching (pruritus), rash
Rare
Affects up to 1 in 1,000 people
- Severe allergic reactions (anaphylaxis): breathing difficulties, skin swelling
- Seizures (convulsions)
- Slow heart rate (bradycardia), elevated blood pressure
- Slow or shallow breathing, shortness of breath (dyspnea)
- Appetite changes, abnormal sensations (tingling, numbness), tremor
- Muscle twitching, weakness, uncoordinated movements
- Fainting (syncope), speech difficulties
- Blurred vision, pupil constriction or dilation
- Urinary retention or difficulty urinating
- Hallucinations, confusion, sleep disturbances, anxiety, nightmares
- Mood changes, decreased cognitive function, impaired judgment
- Drug dependence
Very Rare / Frequency Not Known
Affects fewer than 1 in 10,000 people or cannot be estimated
- Vertigo (balance problems)
- Flushing
- Liver enzyme elevations
- Hypoglycemia (low blood sugar)
- Hyponatremia (low sodium levels causing fatigue, confusion, seizures)
- Worsening of asthma
- Hiccups
- Serotonin syndrome: agitation, hallucinations, coma, fever, rapid heartbeat, unstable blood pressure, involuntary muscle jerking, muscle rigidity, gastrointestinal symptoms
- Adrenal insufficiency (with long-term use)
Psychological side effects: Tramadol Vitabalans can cause various psychological effects that vary in intensity and nature depending on the individual and the duration of treatment. These may include mood swings (usually euphoria, sometimes irritability or dysphoria), changes in activity level (usually decreased, sometimes increased), and diminished cognitive function including impaired judgment and decision-making ability. Rarely, hallucinations, paranoia, or altered perception of reality may occur, especially at higher doses or in susceptible individuals.
Withdrawal symptoms: If Tramadol Vitabalans treatment is discontinued abruptly after prolonged use, withdrawal symptoms may occur. These can include restlessness, anxiety, nervousness, tremor, sweating, difficulty sleeping, and gastrointestinal disturbances such as nausea and diarrhea. In rare cases, more severe symptoms may develop including panic attacks, paranoia, hallucinations, altered perception of reality, tinnitus (ringing in the ears), and unusual sensations such as itching, tingling, and numbness. If you experience any withdrawal symptoms, consult your healthcare provider for guidance on safely tapering the medication.
How Should You Store Tramadol Vitabalans?
Tramadol Vitabalans is a controlled substance in many countries and must be stored securely to prevent access by unauthorized persons, as tramadol can cause serious harm and death in individuals for whom it has not been prescribed. Always keep Tramadol Vitabalans in a locked cabinet or secure location, out of sight and reach of children. Accidental ingestion of even a small number of tablets by a child can be fatal due to the risk of respiratory depression.
No special storage conditions regarding temperature or humidity are required for Tramadol Vitabalans 50 mg tablets. Store the tablets in their original blister packaging until use, which helps protect them from moisture and light. Do not use the medication if you notice any discoloration, damage to tablets, or signs of deterioration. Always check the expiry date printed on the blister pack or carton before use; the expiry date refers to the last day of the indicated month. Do not flush unused Tramadol Vitabalans down the toilet or throw it in household waste, as this can contaminate water supplies and pose risks to others. Return any unused or expired medication to your local pharmacy for safe and environmentally responsible disposal through appropriate take-back programs.
What Does Tramadol Vitabalans Contain?
Each Tramadol Vitabalans tablet contains tramadol hydrochloride 50 mg as the active substance. Tramadol hydrochloride is the salt form of tramadol, a synthetic centrally acting opioid analgesic. The hydrochloride form provides good oral bioavailability and consistent dissolution in the gastrointestinal tract, ensuring reliable absorption and predictable onset of analgesia.
Common inactive ingredients (excipients) found in tramadol tablets include microcrystalline cellulose (a bulking agent), hypromellose (binder), colloidal anhydrous silica (glidant), magnesium stearate (lubricant), and sodium starch glycolate or other disintegrants. Some formulations may also contain lactose monohydrate, talc, polyethylene glycol (macrogol), titanium dioxide, and various iron oxide coloring agents (E172) in the film coating. If you have known lactose intolerance or other dietary restrictions, check the specific package leaflet supplied with your medication, as formulations may differ slightly between batches and markets.
Tramadol Vitabalans is manufactured by Vitabalans Oy, a Finnish pharmaceutical company specializing in generic and over-the-counter medicines. As a generic tramadol product, Tramadol Vitabalans is considered therapeutically equivalent to branded tramadol products that have received regulatory approval, meaning it provides the same clinical effects, safety profile, and quality standards as originator tramadol formulations. Other common tramadol products available in various markets include Tradolan, Tramadol HEXAL, Tramadol STADA, Tramadol Krka, Tramadol Actavis, and Ultram (in the United States).
Frequently Asked Questions About Tramadol Vitabalans
Tramadol Vitabalans 50 mg tablets are used for the treatment of moderate to severe pain in adults and adolescents over 12 years of age. Common indications include acute post-operative pain, pain following trauma or injury, chronic pain conditions such as osteoarthritis and back pain, and cancer-related pain. The active substance tramadol hydrochloride belongs to the opioid analgesic class and works through both mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake, providing pain relief through two complementary pharmacological mechanisms.
Yes, Tramadol Vitabalans carries a recognized risk of dependency, tolerance, and addiction because it contains tramadol, an opioid. While generally considered to have lower abuse potential than stronger opioids like morphine or oxycodone, physical and psychological dependence can develop with repeated use. Risk factors include prolonged use, higher doses, personal or family history of substance abuse, and co-existing psychiatric conditions. Tramadol is classified as a controlled substance in many countries. Always take Tramadol Vitabalans only as prescribed and for the shortest duration necessary, and never share your medication with others.
Combining Tramadol Vitabalans with antidepressants — particularly SSRIs (such as fluoxetine, sertraline, citalopram), SNRIs (such as venlafaxine, duloxetine), and tricyclic antidepressants — significantly increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, rapid heartbeat, fever, muscle rigidity, and loss of coordination. The combination also increases seizure risk. Monoamine oxidase inhibitors (MAOIs) are an absolute contraindication and must not have been used within the previous 14 days. Never start or stop antidepressants while taking Tramadol Vitabalans without first consulting your doctor.
The maximum recommended daily dose of Tramadol Vitabalans is 400 mg, equivalent to eight 50 mg tablets taken over 24 hours. Exceeding this dose significantly increases the risk of seizures, serotonin syndrome, respiratory depression, and other serious adverse effects. The usual adult dose is 50–100 mg every 4–6 hours as needed for pain. Dose reductions and extended dosing intervals are required for elderly patients over 75 years, patients with mild to moderate kidney or liver impairment (typically maximum 200 mg per day), and Tramadol Vitabalans should not be used in those with severe renal or hepatic impairment.
Abruptly stopping Tramadol Vitabalans after prolonged use can trigger withdrawal symptoms including restlessness, anxiety, nervousness, tremor, insomnia, sweating, nausea, diarrhea, and generalized pain. In rare cases, more severe symptoms may occur: panic attacks, paranoia, hallucinations, altered perception of reality, tinnitus (ringing in the ears), and unusual sensory experiences such as itching or tingling. Tramadol Vitabalans should always be tapered gradually under medical supervision. Your doctor will create a personalized tapering schedule that safely reduces the dose over days or weeks, depending on the duration and dose of prior use.
Tramadol Vitabalans should not be used during pregnancy due to limited safety data and potential risks to the fetus and newborn. Long-term use during pregnancy can cause neonatal withdrawal syndrome, with symptoms including excessive crying, tremors, feeding difficulties, and irritability requiring specialized neonatal care. Tramadol is excreted in breast milk; a single dose does not usually require interrupting breastfeeding, but if repeated doses are needed, breastfeeding should be discontinued. Always discuss alternative pain management options with your healthcare provider if you are pregnant, planning a pregnancy, or breastfeeding.
No, you should not consume alcohol while taking Tramadol Vitabalans. Alcohol and tramadol both depress the central nervous system, and when combined the effects are dangerously amplified. Concurrent use substantially increases the risk of excessive sedation, respiratory depression (slow or shallow breathing), loss of consciousness, and potentially fatal overdose. Even small amounts of alcohol can cause dangerous interactions. If you regularly consume alcohol, inform your doctor before starting Tramadol Vitabalans so an appropriate pain management strategy can be chosen.
References
This article is based on the following peer-reviewed sources and international clinical guidelines. All medical claims are supported by evidence level 1A or higher.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Tramadol Hydrochloride — Summary of Product Characteristics. Amsterdam: EMA; 2024.
- U.S. Food and Drug Administration (FDA). Ultram (Tramadol Hydrochloride) — Full Prescribing Information. Silver Spring, MD: FDA; 2023.
- National Institute for Health and Care Excellence (NICE). Chronic Pain (Primary and Secondary) in Over 16s: Assessment and Management (NG193). London: NICE; 2024.
- British National Formulary (BNF). Tramadol Hydrochloride — Drug Monograph. London: BMJ Group and Pharmaceutical Press; 2025.
- Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. doi:10.2165/00003088-200443130-00004
- Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44-51. doi:10.1213/ANE.0000000000001683
- Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med. 2015;175(2):186-193. doi:10.1001/jamainternmed.2014.6512
- Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007;82(1):41-47. doi:10.1038/sj.clpt.6100152
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
Medical Review & Editorial Team
This article has been written and reviewed by our medical editorial team, comprising licensed physicians specializing in clinical pharmacology, pain medicine, and addiction medicine. All content follows the GRADE evidence framework and adheres to WHO, EMA, and FDA guidelines.
iMedic Medical Editorial Team — Specialists in Clinical Pharmacology and Pain Medicine
iMedic Medical Review Board — Independent expert panel reviewing all content according to international guidelines
Level 1A — Based on systematic reviews, randomized controlled trials, and international clinical guidelines (WHO, EMA, FDA, NICE, BNF)
— Content reviewed and updated to reflect current prescribing information and safety data